Table 1 Clinical characteristics

Age, median (range)

53.1 (21.9–82.7)

27.6 (23.3–74.9)

58.3 (21.9–82.7)

Sex distribution (% female)

81.6

66.7

88.5

BMI, kg/m² median (range)

24.8 (14.9–39.9)

25.6 (18.5–30.3)

23.8 (14.9–39.9)

Number prior CDI episodes, median (range)

5 (3–13)

4.5 (3–7)

5 (3–13)

Number prior metronidazole courses, median (range)

1 (0–8)

1 (0–2)

1 (0–8)

Patients treated with at least one prior course of metronidazole, n (%)

33 (86.8%)

9 (75%)

24 (92.3%)

Number prior vancomycin 10–14 day courses, median (range)

2 (0–4)

2 (0–4)

2 (0–3)

Patients treated with at least one prior course of vancomycin, n (%)

36 (94.7%)

11 (91.7%)

25 (96.2%)

Number prior vancomycin tapers, median (range)

1 (0–5)

1 (0–1)

1 (0–5)

Patients treated with at least one prior course of vancomycin taper, n (%)

26 (68.4%)

7 (58.3%)

19 (73.1%)

Number prior fidaxomicin courses, median (range)

0 (0–4)

0 (0–2)

0 (0–4)

Patients treated with at least one prior course of fidaxomicin, n (%)

16 (61.5%)

5 (41.7%)

16 (61.5%)

Related donors, n (%)

12 (31.6%)

0 (0%)

12 (46.2%)

Recurrent CDI within 24 months of FMT, n (%)

5 (13.2%)

3 (25%)

2 (7.7%)